Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
JPMorgan Ultra Short Income ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.94 (market cap $29.60B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYJPST
Market Cap
$29.60B
Sector
HealthLeveraged / Inverse
52-Week High
$491.22$50.78
52-Week Low
$205.48$50.40
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

JPMorgan Ultra Short Income ETF

JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% daily, with a bearish technical signal driven by moving averages. The fund focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends, including recent $0.17 payouts. Institutional holdings have increased, as seen in 13F filings from Financial Management Professionals Inc. and Ashton Thomas Securities LLC in Q2 2026, indicating steady investor interest amid a rising rate environment.

The outlook for JPST is stable, benefiting from its low-risk profile in volatile markets, but faces headwinds from potential Fed rate hikes that could pressure short-term bond yields. Risks include interest rate sensitivity and inflation concerns, yet it remains a core holding for conservative investors seeking yield with minimal volatility.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST